Generex Biotechnology expands of ANtigen express cancer trials to include prostate cancer patients
Clinical trials are initiated at the Euroclinic in Athens, Greece
10-Aug-2006 -
Generex Biotechnology Corporation has entered into an agreement with the Euroclinic in Athens, Greece to commence clinical trials on a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary Antigen Express, Inc. The compound has been in clinical trials for more than a year ...
breast cancer
clinical trials
Generex Biotechnology
+5